Our chemical and biological study of 1-benzhydryl-piperazine-based HDAC inhibitors illustrates how side chain modifications (one carbon atom in aliphatic linkers and the introduction of an aromatic linker) can be exploited to alter the anti-cancer and anti-metastatic properties of HDAC inhibitors. Here, HDAC9 is linked to cancer.